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Abstract
The influence of dopamine receptor agonists in the Iransdermal and oral forms of drugs and amantadine for a non-motor 
autonomic fluctuations of patients with different duration of the disease during the treatment of Parkinson's in a stable 
dose of levodopa were established. It was analysed, that the use of dopamine receptor agonists in the iransdermal and 
oral forms of drugs reduce the frequency and duration of vegetative non-motor fluctuations of patients with Parkinson's 
disease. The use of amantadine sulphate has little effect in a decrease of non-motor autonomic fluctuations.
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Parkinson’s disease - is a steadily progressive 
neurodegcncrativc disease characterized by a 
gradual increase in m otor, m ental and au tono­
mic disorders.
But despite the advances in the treatm ent o f 
the disease, it retains a progressive course and 
inevitably leads to  disability o f  patients [1,2],
As the disease progresses in its clinical picture 
non-m otor m anifestations are getting increasing­
ly im portant, which can largely affect the quality 
o f  life o f patients and their degree o f disability 
than  the classic m oto r sym ptom s o f  Parkinson’s 
disease [2-5].
N on-m otor fluctuations arise mainly during 
the "off" time and decrease or disappear after 
levodopa adm inistration. All non-m otor symp­
tom s that occur with different phases o f  levodo­
pa action are divided into the following groups: 
vegetative, m ental and sensory. Vegetative fluc­
tuations dom inate in the clinical picture o f non­
m otor sym ptom s [1-4,6-9], The appearance of 
the fluctuations depends on the severity and du­
ration  o f  the disease stage at Hoen and Y ahr, the 
duration  o f  use and the dose o f  levodopa [5,6,8- 
10], W hen disease onset early fluctuations appear 
faster and are pronounced. Some role o f gender 
factors: wom en's au tonom ic fluctuations are 
observed m ore frequently  than  men’s ones 
[2,9,10],
N on-m otor m anifestations may outpace the 
developm ent o f  the disease and m otor worsem- 
ing may persist after the reduction o f  symptoms 
o f Parkinson's disease. This is explained by the 
involvement o f the basal ganglia and closely 
related limbic, diencephalic, brainstem  struc- •
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lures, the frontal cortex [2,7-12], The approaches 
to  treatm ent o f  non-m oto r fluctuations arc not 
well developed, but should be based on the sam e 
principles as the correction  o f  m oto r fluctua­
tions. Ft is im portant to  establish clearly in which 
phase o f  certain sym ptom s appear [2,5-9].
The aim o f  ou r study was to investigate the 
influence o f  dopam ine receptor agonists in the 
transderm al and oral form s o f  d rugs and am an­
tadine on non-m otor autonom ic fluctuations o f 
patients with a different du ration  o f  the disease 
during the treatm ent o f  Parkinson's is a stable 
dose o f levodopa.
M ateria l and methods. We exam ined 30 
patients (20 women and  10 men) with an akine­
tic-trem or form o f  Parkinson’s disease who were 
treated in the neurology departm ent o f  Poltava 
Regional Clinical H ospital by N.V.Sklifosovsky 
and observed in the center o f  Parkinson at the 
D epartm ent o f  N ervous Diseases with neuro­
surgery and medical genetics H SEEU  "U krai­
nian Medical Dental Academy". Diagnosis was 
made according to  the standard  o f  the Inter­
national Classification o f  Diseases o f  the X revi­
sion. The verification o f  the diagnosis o f  
Parkinson's disease was carried out according to 
the international clinical diagnostic criteria o f 
the Bank o f  the brain o f  Parkinson’s Disease 
Society o f  G reat Britain. The severity o f  disease 
was determ ined by the rating scale Unified 
Parkinson's Disease R ating (U PD RS).
The average age was 60.5±10.8 years. The 
average duration  o f disease - 10.9±4.5 years. The 
stage o f the disease was evaluated on a scale 
Hoen and Yahr. The rating vegetative state o f
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patients was conducted by a questionnaire to 
assess autonomic functions. The quality of life o f 
patients was determined by PDQ-39 scale. All 
patients received continuous therapy with lev- 
odopa drugs 4 times a day (daily dose of lev- 
odopa was 375-500 mg). The disease severity on 
a scale Hoen and Yahr was - 3.5±0.5.
By the method of the treatment, patients were 
divided into three groups: group 1(10 patients) - 
the duration of receiving levodopa 7.3+1.5 years 
- received rotigotine as a transdermal patch in 
the form of "Neupro" 8 mg 1 time a day for 3 
weeks; group 2 (10 patients), the duration of 
receiving levodopa 6.6±1.4 years - pramipexole 
as a drug "Pramipex" 1.5 mg per day for three 
divided doses for 3 weeks (after gradual, within 
3 weeks of titration dose); group 3 (10 patients),
the duration o f treatment with levodopa 4.311.6 
years - received amantadine sulfate oral dose of 
300 mg a day in three divided doses for 3 weeks. 
The control group - 10 patients (4 W'omen and 6 
men), duration  o f treatm ent with levodopa 
5.211.8 years, which were treated only by lev­
odopa 4 times a day (the duration of receiving 
levodopa 3.110.9 years).
The general clinical, neurological and neu­
ropsychological examination was carried out for 
all patients at the beginning and end o f treat­
ment. The patients kept diaries to assess periods 
o f activation, deactivation, and appearances 
non-motor fluctuations o f throughout the study.
Results and discussion. Features of autonomic 
disorders were evaluated on a scale o f UPDRS. 
Autonomic fluctuations are shown in Table 1.
Table 1
Patient's basic autonomic disfunction with Parkinson's disease at the beginning of treatment (%)
Signs 1 group 
(n~10)
11 group 
(n= 10)
111 group 
(n=10)
Control
(n=10)
Hyperhydrosis 60 55 55 50
Feeling hot/cold 20 10 10 20
Hypersalivation 40 50 50 30
Abdominal discomfort 20 30 20 20
Frequent
urination/dysuria/incontinence
50 30 30 30
Sexual dysfunctions 40 35 40 20
Orthostatic hypotension 10 5 10 10
Dyspnea/compulsive cough 20 10 30 20
Constipation 70 60 60 70
Table 2
The emergence of non-motor symptoms of autonomic in the action phase of levodopa (*/•)
Signs I group 
(n=10)
11 group 
(n=10)
III group
_____ (n=10)
Control
(n=10)
Period
«on»
Period
«off»
Period
«on»
Period
«off>>
Period
«on»
Period
«off>>
Period
«on»
Period
«ofT»
Hyperhydrosis 10 50 20 40 20 50 30 60
Feeling hot/cold 10 40 20 30 10 40 10 40
Hypersalivation 20 50 30 40 20 50 40 60
Abdominal
discomfort
20 30 10 40 20 50 10 30
Frequent
urination/dysuria/
incontinence
20 60 10 40 20 30 10 50
Orthostatic
hypotension
10 20 10 30 20 20 10 10
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The highest frequency of autonomic disorders 
observed in all three groups of women and was pre­
sented in the form of constipation, dysurinational dis­
orders, hyperhidrosis, hypersalivation. The non­
motor autonomic dysfunctions are more pronounced 
during the "off' action of levodopa. Sometimes bipha- 
sic fluctuations are observed (Table 2.).
You can see from the table 2 the most fre­
quent autonom ic fluctuations appeared in "off' 
period: sweating (50% o f the off period in the 
first group and 60% - in the second group of 
patients), salivation (50% in the first and second 
groups during the 60% off - in the control group
of patients), the feeling hot and cold, urinary dis­
orders. Hypcsalivation can indirectly be attrib­
uted to the non-m otor autonom ic symptoms, 
because it depends o f directly on swallowing 
function. However, a proved stimulating effect 
o f levodopa on saliva production.
The rare vegetative manifestations include: 
abdominal discomfort, orthostatic hypotension, 
nausea, respiratory function as breathlessness, 
chest's discomfort or compulsive cough. In the 
course o f the study, after treatm ent in groups of 
patients there were changes in autonom ic mani­
festations fluctuations (Table 3).
Table 3
Patient's basic autonomic disfunction with Parkinson's disease at the beginning of treatment (%)
Signs 1 group 
(n=10)
11 group 
(n=10)
III group 
(n=10)
Control
(n=10)
Period
«off»
Period
«off»
Period
«off»
Period
«off»
Hyprehydrosis 30* 10* 30* 60
Feelings hot/cold 40 10* 30 40
Hypersalivation 40 20 40 60
Abdominal discomfort 10 20 40 30
Frequent
urination/dysuria/
incontinence
20* 20 30* 50
Orthostatic hypotension 40* 10 10 10
Note: * - p<0.05 - compared with the group of patients before and after treatment.
After treatment there was a positive effect as a Conclusion. Thus, as a result of studies, the 
decrease in non-m otor vegetative symptoms in positive results obtained in the form of reducing 
groups, treated with rotigotine and pramipaxole. the frequency and duration of vegetative non- 
In the first group of patients, who were treated motor fluctuations of patients with Parkinson's 
with rotigotine, an increased incidence of ortosta- disease. It’s found that the use for rotigotine has 
tic hypotension was noticed, but cases of hypoten- a positive effect, but it is desirable to use in the 
sion were observed in other groups of patients, elderly and young people with Parkinson disease 
Most likely a symptom of the advanced stage of in the absence of orthostatic hypotension and 
the disease of older patients. However, the pres- allergic reactions in anamnesis, 
ence of orthostatic hypotension may be due to the Using amantadine sulphate has little effect, 
amplification of dopaminergic therapy (dopamine compared to the efTect on levodopa-induced 
receptor agonists). Some patients had cutaneous motor dyskinesia. The application of a dopamine 
manifestations in the form of itching, redness at receptor agonist in the form of a transdermal 
the place o f transdermal patch application. patch and oral drugs in average therapeutic dose
The positive results were found in groups of (1.5 mg) has a positive efTect and may be rccom- 
patients treated with pramipcxolc and amanta- mended for the non-motor vegetative fluctua- 
dine sulfate More rapid effect was observed lions correction for Parkinson’s disease patients 
w hen pramipcxolc was used at a dose of 1.5 mg on the base of levodopa treatment in a stable 
per day (the second group of patients). dose.
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KOPPEKUHH HEMOTOPlIbIX BK.rETATHBHMX yA H IIli
*H*II KOJIE3HU IIAPKHIICOHA HA <I>OHE JlFB(>a<)l IATEPAI HIM
l apMIIIIK E.A., K.M.II.
HI 3 i y  ' yKpauncKiiH MedutiuncKciH cmoMamojioeu'iecKOH aKadeMiu*", llomuiea. y^pauna
ripoBCACiio inyM cm tc B jitta im x aro im cT O B  AocJiaMimoBbix p cu c itT o p o B  b bmac T p a iic A cp M an b ito fi <}>opMbi h 
n ep o paA bH bix  iipcttaparoB it aMsurraAHHOB »ta tchciiiic iicMOTopiibix B crcT aniB iiM x (JjayKTyaiiiiH  y 
G ojii.m .ix c p a j i to f t  juiit icjibiioci t»to tcmchiiji 6o;icjhii H a p K iu ic o iia  n a  (Jiohc CTa6 HAbHofi ;u>3bi .icboaoiim 
O t MCHCIIO, MTO npHMCHCHHC arOHHCTOB AO())aMIIHOBblX PCUCIITOPOB B BMAC TpaHCACpMaAbHOti M 
IICpOpaJIbHOfl ()>opM IIMCCT IIOJIOJKMTCJIbltblft 3<t>(|>CKT H BIIAC CHH/KCHIfSI MaCTOTbl H AAHTCAbHOCTH 
BClCTaTItBHHX HCMOTOpHbIX (|>;iyKTyaHMH y naUHCHTOB c  6 oAC3HbK> riapK H H C O H a. H c n o A b 3 0 B a im c  
a M a in a / t im a  cy ;ib ())a ra  oK aibiB acT  HC3HaHHTejibHbiM k JhJjckt n a  jicBO A ona-M H A yunpycM bie M O Topiibic
AHCKMIIC3HH.
K iio'ichmc cnoBJi: Gojicjiii, flap K iu tc o H a , hcmotophuc  (JwiyKTyamiii, :icB o ;io n o T cp an n H
